How many restricted share units does the AUTL CFO hold according to the Form 3?

Robert Dolski holds 83,300 restricted share units in Autolus Therapeutics. These RSUs convert into American Depositary Shares on vesting, forming a key part of his long-term incentive compensation and directly linking his future upside to the company’s share performance.

Autolus Therapeutics (AUTL) CFO details stock option and RSU awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Autolus Therapeutics plc Chief Financial Officer Robert Dolski filed an initial ownership report showing existing equity awards, rather than new market transactions. The filing lists several share option grants over American Depositary Shares with exercise prices between $1.46 and $2.50, expiring from 2033 to 2036, plus 83,300 restricted share units that vest annually starting on January 26, 2027.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Dolski Robert

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Share Option (right to buy) — 500,000 shares (Direct); Restricted Share Units — 83,300 shares (Direct)

Footnotes (1)

This option vested 25% on July 17, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on October 12, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on March 14, 2026 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.

Understanding Insider Trading Forms →

03/18/2026 - 07:54 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dolski Robert

(Last)

(First)

(Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON

W12 7FP

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (right to buy)	⁽¹⁾	07/17/2033	American Depositary Shares	500,000	$2.5	D
Share Option (right to buy)	⁽²⁾	10/12/2033	American Depositary Shares	250,000	$2.31	D
Share Option (right to buy)	⁽³⁾	03/14/2035	American Depositary Shares	300,000	$1.89	D
Share Option (right to buy)	⁽⁴⁾	01/26/2036	American Depositary Shares	375,000	$1.46	D
Restricted Share Units	⁽⁵⁾	⁽⁵⁾	American Depositary Shares	83,300	⁽⁶⁾	D

Explanation of Responses:

1. This option vested 25% on July 17, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter.

2. This option vested 25% on October 12, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter.

3. This option vested 25% on March 14, 2026 and the remainder vested or vests in 36 equal monthly installments thereafter.

4. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.

5. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.

6. Each RSU represents a contingent right to receive one Issuer American Depositary Share.

	/s/ Robert Dolski	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Autolus Therapeutics (AUTL) CFO Robert Dolski report in this Form 3?

The Form 3 shows Robert Dolski’s existing equity awards in Autolus Therapeutics. It lists multiple stock option grants over American Depositary Shares and 83,300 restricted share units, providing a baseline of his compensation-linked ownership position as Chief Financial Officer.

What are the key vesting terms for the Autolus Therapeutics (AUTL) CFO’s RSUs and options?

The RSUs vest in four equal annual installments starting on January 26, 2027. Option grants generally vest 25% on specified initial dates, with the remaining 75% vesting in 36 equal monthly installments, aligning Dolski’s incentives with multi‑year company performance.

Are there any stock purchases or sales reported for Autolus Therapeutics (AUTL) in this Form 3?

No stock purchases or sales are reported in this Form 3. The filing only lists existing stock option and restricted share unit awards held by CFO Robert Dolski, serving as an initial snapshot of his derivative and RSU holdings, not current trading activity.

What exercise prices are attached to the AUTL CFO’s stock options in this filing?

The filing shows several option grants with exercise prices of $2.50, $2.31, $1.89 and $1.46 per American Depositary Share. These strike prices define the cost at which Dolski can buy shares, creating potential upside if market prices exceed those levels.